Clinical Trial Detail

NCT ID NCT02203526
Title Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

diffuse large B-cell lymphoma

central nervous system lymphoma

Therapies

Dexamethasone + Etoposide + Ibrutinib + Pegylated liposomal-doxorubicin + Temozolomide

Cytarabine

Rituximab

Age Groups: adult

No variant requirements are available.